{"product_id":"complete-response-clinical-review-nda-bla-drugs-ataluren-2016-bulevirtide-2022-roxadustat-2021-gefapixant-2023","title":"Complete Response \u0026 Clinical Review – NDA\/BLA Drugs (Ataluren 2016, Bulevirtide 2022, Roxadustat 2021, Gefapixant 2023)","description":"\u003cb\u003eRequest Contents:\u003c\/b\u003e Complete response letters and clinical review reports for NDA\/BLA drugs (not available in Drug@FDA database):\nAtaluren (2016)\nBulevirtide (2022)\nRoxadustat (2021)\nGefapixant (2023)","brand":"FDA","offers":[{"title":"Default Title","offer_id":50791082950820,"sku":"FDAFT254","price":89.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/foiadocs.com\/products\/complete-response-clinical-review-nda-bla-drugs-ataluren-2016-bulevirtide-2022-roxadustat-2021-gefapixant-2023","provider":"FOIA Document Source","version":"1.0","type":"link"}